Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 6:50 p.m.

    📋 Delcath Systems Inc (DCTH) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 16:41:41

    Event Type: Clinical Trial Update

    Event Details:

    Delcath Systems Inc (DCTH) Announces Clinical Trial Update Delcath Systems Inc (DCTH) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: updates
    • Collaboration: Delcath Systems
    • Updated Timeline: Fourth Quarter and Full Year 2025, Preliminary Fourth Quarter and Full-Year 2025
      • Currently 25 active centers
      • Approximately 140% growth in HEPZATO procedure volume in 2025 versus 2024
      • Independent investigators presented results from the Phase 2 CHOPIN trial sponsored by Leiden University Medical Center evaluating CHEMOSAT with ipilimumab and nivolumab in metastatic uveal melanoma at the 2025 European Society of Medical Oncology Annual Congress showing a significant improvement in one

    🔬 Clinical Development Pipeline (Delcath Systems Inc):

    Product Type Development Stage Therapeutic Area Source
    Melphalan DEVICE Phase PHASE1 Metastatic Melanoma ClinicalTrials.gov
    Melphalan/HDS (Percutaneous Hepatic Perfusion) DRUG Phase PHASE2 Metastatic Uveal Melanoma ClinicalTrials.gov
    Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab DRUG Phase PHASE2 Refractory Metastatic Colorectal Cancer ClinicalTrials.gov
    Nivolumab and Relatlimab DRUG Phase PHASE1 Metastatic Melanoma ClinicalTrials.gov
    Tebentafusp DRUG Phase PHASE2 Metastatic Uveal Melanoma ClinicalTrials.gov
    Trifluridine-tipiracil plus Bevacizumab Alone DRUG Phase PHASE2 Refractory Metastatic Colorectal Cancer ClinicalTrials.gov
    Percutaneous Hepatic Perfusion DEVICE Preclinical Metastatic Liver Cancer ClinicalTrials.gov
    isolated perfusion DRUG Phase PHASE2 Cancer ClinicalTrials.gov
    Sorafenib DRUG Phase PHASE2 Hepatocellular Carcinoma (HCC) ClinicalTrials.gov
    Melphalan/HDS DEVICE Phase PHASE2 Hepatocellular Carcinoma (HCC) ClinicalTrials.gov
    hepatic artery embolization PROCEDURE Phase PHASE3 Intraocular Melanoma ClinicalTrials.gov
    systemic chemotherapy DRUG Phase PHASE3 Intraocular Melanoma ClinicalTrials.gov
    regional chemotherapy DRUG Phase PHASE3 Intraocular Melanoma ClinicalTrials.gov
    Cisplatin and Gemcitabine DRUG Phase PHASE2 Bile Duct Cancer ClinicalTrials.gov
    Delcath Hepatic Delivery System DEVICE Phase PHASE2 Hepatocellular Carcinoma ClinicalTrials.gov
    Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) DRUG Phase PHASE2 Metastatic Breast Cancer in the Liver ClinicalTrials.gov
    Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) DRUG Phase PHASE2 Metastatic Breast Cancer in the Liver ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Delcath Systems Inc
    • Ticker Symbol: DCTH

Search

News categories